Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug;9(4):552-5.
doi: 10.1093/ckj/sfw022. Epub 2016 Jun 5.

Ofatumumab treatment in lupus nephritis patients

Malena Loberg Haarhaus  1 , Elisabet Svenungsson  1 , Iva Gunnarsson  1
Affiliations

Ofatumumab treatment in lupus nephritis patients

Malena Loberg Haarhaus et al. Clin Kidney J. 2016 Aug.

Abstract

Rituximab is frequently used in systemic lupus erythematosus; however, side effects such as infusion-related reactions limit its use. In this case report, we describe, for the first time, treatment with ofatumumab in four patients with lupus nephritis. The treatment was well tolerated in three of the patients, and a reduction of proteinuria was seen in all cases. This emphasizes the importance of alternative B-cell-depleting therapies in patients with an initial good response to rituximab, but who develop side effects.

Keywords: infusion reactions; lupus nephritis; ofatumumab; rituximab; systemic lupus erythematosus.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Follow-up of four patients with lupus nephritis, treated with ofatumumab. The last rituximab dose before switch is indicated by white arrow. Ofatumumab doses are indicated by black arrows. Serum creatinine (triangles, left y-axis), urine albumine/creatinine (U-alb/crea, circles, left y-axis) and anti-double stranded DNA (anti-dsDNA, squares, right y-axis) are shown. Time is indicated on x-axis in months.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Merrill JT, Neuwelt CM, Wallace DJ et al. . Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222–233 - PMC - PubMed
    1. Rovin BH, Furie R, Latinis K et al. . Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215–1226 - PubMed
    1. Terrier B, Amoura Z, Ravaud P et al. . Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010; 62: 2458–2466 - PubMed
    1. Fernandez-Nebro A, de la Fuente JL, Carreno L et al. . Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus 2012; 21: 1063–1076 - PubMed
    1. Gottenberg JE, Guillevin L, Lambotte O et al. . Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 913–920 - PMC - PubMed

LinkOut - more resources